Hel 13-5
Based on 1 Customer Validation
Hel 13-5 is a monomeric, lipophilic, basic amphipathic α-helical synthetic peptide composed of 18 amino acid residues. Hel 13-5 is designed as a substitute for proteins in artificial pulmonary surfactants, and it mimics the interaction between the N-terminal fragment of human pulmonary surfactant protein B and lipids. Hel 13-5 can bind to phospholipids for the development of pulmonary surfactant model systems. Hel 13-5 can be used in studies related to respiratory distress syndrome.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.56%
- CAS No.: 177942-21-1
- Formule: C113H204N24O19
- Masse moléculaire:2202.98
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
Hel 13-5 (10 μM) forms an α-helical structure in aqueous buffer and retains α-helical structural characteristics in the presence of neutral, acidic, and soy lecithin liposomes at 10 μM concentration[1].
Hel 13-5 (20 μM) exhibits near-complete hemolytic activity at an approximate concentration of 20 μM, with activity increasing in a concentration-dependent manner; this activity profile is shared with its derivative Hel 13-5D3[1].
Hel 13-5 (0.01-0.025 molar fraction) alters the phase domain morphology of DPPG and DPPC/DPPG (4:1) Langmuir monolayers, reducing LC domain size in both systems, with more pronounced dispersion in DPPG/Hel 13-5 due to specific electrostatic interactions[2].
Hel 13-5 (0.01-0.1 molar fraction) induces distinct phase behavior in DPPG Langmuir monolayers (forming two independent LC domain populations at X_Hel 13-5 = 0.01-0.05) due to specific electrostatic interactions, while only reducing LC domain size in DPPC/DPPG (4:1) monolayers due to dominant DPPC-DPPG miscibility[2].
Hel 13-5 (0.1 molar fraction) forms larger, stabilized squeezed-out aggregates in DPPG LB films (retaining structure down to 35 mN m−1 during expansion) due to specific electrostatic interactions, while forming smaller, rapidly respreading aggregates in DPPC/DPPG (4:1) and DPPC films[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The Hel 13-5 (0.1 mL (20 mg/mL); respiratory tract)-containing Murosurf SLP mixture suppresses egg white albumin-induced pulmonary resistance elevation and reduces allergic inflammatory cell infiltration in Brown Norway rat asthma models[1].
Pulmonary surfactant preparations containing Hel 13-5 provide improvement to lung function and activity in surfactant-deficient rat[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Brown Norway rats[1]
-
Dosage:0.1 mL (20 mg/mL) (as part of Murosurf SLP mixture, 2.5% weight fraction of Hel 13-5)
-
Administration:respiratory tract
-
Result:Significantly suppressed egg white albumin-induced increase in pulmonary resistance within 45 minutes of exposure.
Reduced total leukocyte counts in bronchoalveolar lavage fluid.
Decreased the number of acidocytes and neutrophils in bronchoalveolar lavage fluid.
Increased macrophage counts in bronchoalveolar lavage fluid compared to untreated sensitized rats.
Chemical Information
-
CAS No. 177942-21-1
-
Appearance Solid
-
Masse moléculaire 2202.98
-
Formule C113H204N24O19
-
Color White to off-white
-
Sequence
Lys-Leu-Leu-Lys-Leu-Leu-Leu-Lys-Leu-Trp-Leu-Lys-Leu-Leu-Lys-Leu-Leu-Leu
-
Sequence Shortening
KLLKLLLKLWLKLLKLLL
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureté et documentation
-
Fiche technique (264 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Nakamura Y, et al. Improvement of pulmonary surfactant activity by introducing D-amino acids into highly hydrophobic amphiphilic α-peptide Hel 13-5. Biochim Biophys Acta. 2014;1838(8):2046-2052. [Content Brief]
[2]. Nakahara H, et al. Pulmonary surfactant model systems catch the specific interaction of an amphiphilic peptide with anionic phospholipid. Biophys J. 2009;96(4):1415-1429. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Hel 13-5 Related Classifications
HY-P4371 Related Classifications
Powered by Bioz
Keywords
- Hel 13-5
- 177942-21-1
- Biochemical Assay Reagents
- surfactant protein B N-terminal segment
- hemolytic activity
- Brown Norway rat asthma models
- pulmonary surfactants
- Wistar rats
- soy lecithin liposomes
- phospholipid monolayers
- dipalmitoylphosphatidylglycerol
- air-water interface monolayers
- respiratory distress syndrome
- Inhibitor
- inhibitor
- inhibit